{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:06:42Z","timestamp":1775070402074,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,10,27]],"date-time":"2003-10-27T00:00:00Z","timestamp":1067212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2004,1,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inflammation and gonadotropins are hypothesized to influence ovarian carcinogenesis. In a prospective study, we evaluated ovarian cancer risk associated with self\u2010reported use of medications that influence inflammation or gonadotropin levels. The Breast Cancer Detection Demonstration Project Follow\u2010Up Study enrolled 61,431 women in 1979 and used telephone interviews and 3 mailed questionnaires through 1998 to update risk factor information and identify incident ovarian cancers. The 1992\u201395 questionnaire ascertained medication use, including duration and frequency of use for aspirin, acetaminophen, other nonsteroidal anti\u2010inflammatory drugs (NSAIDs), tranquilizers and histamine\u2010receptor antagonists. A Poisson regression analysis generated rate ratios (RRs) and 95% confidence intervals (CIs) for the 31,364 women who were at risk of ovarian cancer and responded to the questionnaire that queried regular medication use. One hundred sixteen women developed ovarian cancer during follow\u2010up. None of the anti\u2010inflammatory medications was associated with ovarian cancer, but the RR for more than 1 aspirin per day for 1 year or longer was 0.56 (95% CI 0.20\u20131.5) and the RR for more than 5 years of regular \u201cother NSAID\u201d use was 2.0 (95% CI 0.95\u20134.2). Regular tranquilizer use was not associated with ovarian cancer, but histamine\u2010receptor antagonists used regularly for more than 5 years (RR = 3.6, 95% CI 1.4\u20139.1) or more than once daily (RR = 3.1, 95% CI 1.5\u20136.5) appeared to increase risk. In our study, neither anti\u2010inflammatory medications nor anti\u2010psychotic medications were associated with ovarian cancer. Potential associations with histamine\u2010receptor antagonists may warrant further study. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.11538","type":"journal-article","created":{"date-parts":[[2004,6,2]],"date-time":"2004-06-02T14:21:46Z","timestamp":1086186106000},"page":"281-286","source":"Crossref","is-referenced-by-count":45,"title":["Medication use and risk of ovarian carcinoma: A prospective study"],"prefix":"10.1002","volume":"108","author":[{"suffix":"Jr.","given":"James V.","family":"Lacey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Hartge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Schatzkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Schairer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,27]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"255","article-title":"Epidemiology and risk assessment for ovarian cancer","volume":"25","author":"Daly M","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_6_3_2","first-page":"315","article-title":"Ovarian cancer screening","volume":"25","author":"Rosenthal A","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7186.786"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116427"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)08064-1"},{"key":"e_1_2_6_7_2","first-page":"903","article-title":"Regular use of analgesic drugs and ovarian cancer risk","volume":"10","author":"Moysich KB","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_8_2","first-page":"933","article-title":"A case\u2010control study of analgesic use and ovarian cancer","volume":"9","author":"Rosenberg L","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016380917625"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60745-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1581"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.5.303.33189"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008373616424"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.17.1459"},{"key":"e_1_2_6_15_2","first-page":"202","article-title":"Effects of nonsteroidal anti\u2010inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents","volume":"8","author":"Rodriguez\u2010Burford C","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.23.1774"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00052773"},{"key":"e_1_2_6_18_2","first-page":"697","article-title":"Psychotropic medication use and risk of epithelial ovarian cancer","volume":"7","author":"Harlow BL","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200003000-00015"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/22.2.155"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90169-W"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01831376"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.4.485"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.334"},{"key":"e_1_2_6_25_2","volume-title":"EPICURE","author":"Preston DL","year":"1996"},{"key":"e_1_2_6_26_2","series-title":"Statistical methods in cancer research","volume-title":"The design and analysis of cohort studies","author":"Breslow NE","year":"1987"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/pmed.2001.0945"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013969611593"},{"key":"e_1_2_6_29_2","first-page":"7","article-title":"Comparison of the tumor inhibiting effects of three histamine H2\u2010receptor antagonists","volume":"3","author":"Tutton PJM","year":"1983","journal-title":"Anticancer Res"},{"key":"e_1_2_6_30_2","first-page":"319","article-title":"Cimetidine use and risk of prostate and breast cancer","volume":"9","author":"Rossing MA","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117563"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.11538","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.11538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T10:50:26Z","timestamp":1700218226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.11538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,1,10]]}},"alternative-id":["10.1002\/ijc.11538"],"URL":"https:\/\/doi.org\/10.1002\/ijc.11538","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,27]]}}}